ArticleHereditary cancer in clinical practice2025
BRCA1 promoter hypermethylation is not associated with germline variants in Polish breast cancer patients.
Article in Hereditary cancer in clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher Levels ofMedical sciences (Basel, Switzerland) · 2026Article
- The Complex Path from Mammary Ductal Hyperplasia to Breast Cancer: Elevated Malignancy Risk in Atypical Forms.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundMethylation of BRCA1 has been associated with an increased risk of breast cancer and specific clinical characteristics of the disease. In the British population, the genetic alteration c.-107 A/T has been shown to cause allelic methylation, leading to familial breast and ovarian cancer. However, this variant has not been detected in Polish population. Nonetheless, other genetic variants may still be associated with BRCA1 methylation, highlighting the need for further research. AIM OF STUDY: This study aimed to analyze BRCA1 promoter region to identify germline alterations associated with BRCA1 methylation in peripheral blood DNA. Additionally, the correlation between the detected variants and breast cancer incidence, as well as clinical characteristics, was assessed. MATERIALS AND
methodsOne hundred breast cancer patients with BRCA1 methylation were analyzed using pyrosequencing to quantify methylation levels. Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from these patients to assess BRCA1 expression. In 47 patients with the highest BRCA1 methylation and decreased BRCA1 expression, Sanger sequencing was performed encompassing 643 bp of BRCA1 promoter to identify potential variants associated with methylation and/or breast cancer. A variant was identified and genotyped in multiple patient groups, including 336 BRCA1 methylation-positive women, 1898 unselected breast cancer cases, 2234 healthy controls, and 309 BRCA1 pathogenic variant (PV) carriers. Statistical analyses were performed using Fisher’s exact test and Chi-square test in Stata/IC version 16.1.
resultsThe study identified BRCA1 c.20 + 101 C/G (rs799905) in the promoter region of the gene. However, no significant association was found between rs799905 and BRCA1 methylation or breast cancer risk. Nevertheless, a borderline association was observed between rs799905 and the occurrence of triple-negative breast cancer (TNBC) (p = 0.048) as well as lymph node (LN) metastases (p = 0.046). Among BRCA1 PV carriers, the GG genotype was significantly more frequent, while the CC genotype was 10 times less common compared to non-carriers (p = 0.003).
conclusionRs799905 variant is not associated with BRCA1 methylation breast cancer risk. However, it may be linked to the occurrence of TNBC and LN metastases. Additionally, rs799905 may be associated to some extent with BRCA1 PVs, though further research is needed to clarify the nature of this potential correlation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.